Yahoo
NasdaqCM - Delayed Quote USD

Nektar Therapeutics (NKTR)

86.46 +1.42 (+1.67%)
At close: May 1 at 4:00:00 PM EDT
85.56 -0.90 (-1.04%)
After hours: May 1 at 6:19:07 PM EDT
Trade NKTR on Coinbase
Chart Range Bar
Loading chart for NKTR
  • Previous Close 85.04
  • Open 85.00
  • Bid 86.18 x 100
  • Ask 86.93 x 100
  • Day's Range 84.29 - 87.57
  • 52 Week Range 7.99 - 109.00
  • Volume 689,763
  • Avg. Volume 1,286,288
  • Market Cap (intraday) 2.917B
  • Beta (5Y Monthly) 1.18
  • PE Ratio (TTM) --
  • EPS (TTM) -9.73
  • Earnings Date May 7, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 144.25

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.

www.nektar.com

63

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview: NKTR

Trailing total returns as of 5/1/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

NKTR
104.49%
S&P 500 (^GSPC)
5.62%

1-Year Return

NKTR
638.97%
S&P 500 (^GSPC)
29.01%

3-Year Return

NKTR
648.57%
S&P 500 (^GSPC)
73.47%

5-Year Return

NKTR
70.61%
S&P 500 (^GSPC)
72.92%

Earnings Trends: NKTR

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY25
Revenue 21.81M
Earnings -26.18M

Q1

FY25

Q2

FY25

Q3

FY25

Q4

FY25

-40M
-20M
0
20M

Analyst Insights: NKTR

View More

Analyst Price Targets

95.00
144.25 Average
86.46 Current
185.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 4/21/2026
Analyst Citigroup
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 123 -> 151

Statistics: NKTR

View More

Valuation Measures

Annual
As of 5/1/2026
  • Market Cap

    2.92B

  • Enterprise Value

    2.76B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    26.41

  • Price/Book (mrq)

    32.48

  • Enterprise Value/Revenue

    49.92

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -297.07%

  • Return on Assets (ttm)

    -27.98%

  • Return on Equity (ttm)

    -217.94%

  • Revenue (ttm)

    55.23M

  • Net Income Avi to Common (ttm)

    -164.08M

  • Diluted EPS (ttm)

    -9.73

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    245.75M

  • Total Debt/Equity (mrq)

    165.76%

  • Levered Free Cash Flow (ttm)

    -108.23M

Compare To: NKTR

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights: NKTR

Fair Value

86.46 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: